| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
hCOX-1 40 nM (IC50) hCOX-2 3 nM (IC50)
Human cyclooxygenase-1 (hCOX-1) and human cyclooxygenase-2 (hCOX-2). Mefenamic acid-d4 acts as a competitive inhibitor of hCOX-1 and hCOX-2, with IC50 values of 40 nM for hCOX-1 and 3 uM for hCOX-2. It also binds to COX-2 with a Kd of 4 nM. |
|---|---|
| ln Vitro |
In vitro, mefenamic acid is a competitive inhibitor of hCOX-1 and hCOX-2, with IC50s of 40 nM and 3 uM, respectively. It binds to COX-2 with a Kd of 4 nM and inhibits COX-2-dependent oxygenation of arachidonic acid with a Ki of 10 uM. The deuterated form is used as an internal standard and is not typically tested alone in biological activity assays.
|
| ln Vivo |
No detailed in vivo studies for mefenamic acid-d4 alone are available. The non-deuterated mefenamic acid is clinically used for pain and inflammation, particularly for dysmenorrhea. It reduces menstrual pain by suppressing prostaglandin synthesis in the uterus. In animal models, mefenamic acid exhibits anti-inflammatory, analgesic, and antipyretic effects typical of NSAIDs.
|
| Enzyme Assay |
A competitive COX inhibition assay is performed using purified human COX-1 and COX-2 enzymes. The enzymes are pre-incubated with serially diluted mefenamic acid-d4 (0.1-1000 nM) for 10 minutes. Arachidonic acid (100 uM) is added, and the reaction proceeds for 2 minutes at 37degC. The reaction is stopped, and PGE2 is measured by ELISA. The IC50 is calculated from the dose-response curve. A Kd value for COX-2 binding is determined by surface plasmon resonance (SPR).
|
| Cell Assay |
For in vitro cellular assays, human whole blood is collected from healthy volunteers. For COX-1 activity, blood is allowed to clot at 37degC for 1 hour in the presence of serially diluted mefenamic acid-d4 (0.1-1000 nM), and serum TXB2 levels are measured by ELISA. For COX-2 activity, blood is treated with LPS (10 ug/mL) and incubated with mefenamic acid-d4 for 24 hours, and plasma PGE2 levels are measured by ELISA.
|
| Animal Protocol |
No in vivo animal studies are performed for mefenamic acid-d4 alone as it is an analytical standard. For pharmacokinetic studies in rats, mefenamic acid is administered orally (10-50 mg/kg), and blood samples are collected at multiple time points. Plasma is analyzed by LC-MS/MS using mefenamic acid-d4 as an internal standard to quantify the parent drug and its metabolites.
|
| ADME/Pharmacokinetics |
Mefenamic acid-d4 has a molecular weight of 245.31 g/mol (deuterated) and a formula of C15H11D4NO2. It is soluble in DMSO and organic solvents. The non-deuterated mefenamic acid is rapidly absorbed after oral administration, reaching peak plasma concentrations in 2-4 hours. It is highly protein-bound (>90%) and has a plasma half-life of approximately 2-4 hours. It is metabolized primarily by CYP2C9 and excreted in urine.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for mefenamic acid-d4 are not publicly available. The non-deuterated mefenamic acid is generally well-tolerated at therapeutic doses. Common adverse effects include gastrointestinal disturbances (e.g., nausea, diarrhea, abdominal pain), headache, and dizziness. Rare but serious adverse effects include renal impairment, hepatotoxicity, and agranulocytosis. Prolonged use may increase cardiovascular risk.
|
| References | |
| Additional Infomation |
Mefenamic acid-d4 is a research-grade stable isotope-labeled compound not approved for clinical use. It is intended for use as an internal standard in LC-MS/MS quantification of mefenamic acid in biological matrices for pharmacokinetic, bioequivalence, and drug-drug interaction studies. This product is for laboratory research purposes only, not for human therapeutic use.
|
| Molecular Formula |
C15H11D4NO2
|
|---|---|
| Molecular Weight |
245.31
|
| Exact Mass |
245.135
|
| CAS # |
1216745-79-7
|
| Related CAS # |
Mefenamic acid;61-68-7
|
| PubChem CID |
45359018
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.0 g/cm3
|
| Boiling Point |
398.8±0.0 °C at 760 mmHg
|
| Flash Point |
195.0±0.0 °C
|
| Vapour Pressure |
0.0±0.0 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
5.33
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
292
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1=C(C(=C(C(=C1[2H])C(=O)O)NC2=CC=CC(=C2C)C)[2H])[2H]
|
| InChi Key |
HYYBABOKPJLUIN-KNIGXJNHSA-N
|
| InChi Code |
InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)/i3D,4D,7D,8D
|
| Chemical Name |
2,3,4,5-tetradeuterio-6-(2,3-dimethylanilino)benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0765 mL | 20.3824 mL | 40.7647 mL | |
| 5 mM | 0.8153 mL | 4.0765 mL | 8.1529 mL | |
| 10 mM | 0.4076 mL | 2.0382 mL | 4.0765 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
